TY - JOUR T1 - Efficacy and Safety of 8- or 12 Weeks of Glecaprevir/Pibrentasvir in Patients with Evidence of Portal Hypertension JF - Infect Dis Ther Y1 - 2022 A1 - Brown, RS Jr A1 - Collins, MA A1 - Strasser, SI A1 - Emmett, A A1 - Topp, AS A1 - Burroughs, M A1 - Ferreira, R A1 - Feld, JJ KW - Glecaprevir KW - Hepatitis C KW - Pibrentasvir KW - portal hypertension KW - sustained virologic response VL - 11 SP - 913-924 UR - https://doi.org/10.1007/s40121-022-00599-8 IS - 2 ER -